The S&P 500 ( SNPINDEX: ^GSPC ) , a benchmark for the broader U.S. stock market, has had one of the most volatile years on record. The index lost more than $6 trillion during the two-day trading period after President Donald Trump announced his "Liberation Day" tariffs as the CBOE Volatility ...

He's still got the Midas touch, but even for the Oracle of Omaha, not everything he touches turns to gold.

This year has been rocky for the U.S. stock market. Between the Trump administration's tariff plans ( and subsequent backtracks ) , recession fears, and overall uncertainty, the stock market has been more volatile than usual.Due to the uncertainty, investors have been heading toward value and ...

Roblox ( NYSE: RBLX ) has revolutionized video gaming in many respects. Its ecosystem supports user-created games and fosters social interaction to provide an enjoyable user experience. Taking that approach, it built an environment that draws an average of 98 million daily active users ( DAUs ) ...

There are mammoth opportunities in artificial intelligence ( AI ) for growth investors to consider. AI has the potential to revolutionize companies in multiple industries by making operations more efficient and taking over and/or eliminating mundane and routine tasks along the way.

This trio of quality dividend stocks ranges from $31 per share to $5,600. Yet all three stand out from the crowd as compelling buys.

BTC price requirements are clear as consolidation below all-time highs continues. Can Bitcoin bulls stick to the plan and avoid falling back below $100,000?

The tech-centric Nasdaq Composite ( NASDAQINDEX: ^IXIC ) has doubled over the last five years, which is quite amazing to think about. This included a pandemic, 40-year high inflation, and the recent tariff-driven sell-off in March.The stock market is the greatest wealth-creating machine the world ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna ( NASDAQ: MRNA ) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped.

A short-term setback gives investors a chance to buy this company, growing its share of a projected $1 trillion market.